Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?

YUCEL, S; AKKAYA, E; GUNTEKIN, E; KUKUL, E; DANISMAN, AHMET; Akman, SEMA; BAYKARA, MEHMET

doi:10.1016/j.urology.2004.09.036

Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?

Atıf İçin Kopyala

YUCEL S., AKKAYA E., GUNTEKIN E., KUKUL E., DANISMAN A., Akman S., ...Daha Fazla

UROLOGY, cilt.65, sa.2, ss.369-373, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 2
Basım Tarihi: 2005
Doi Numarası: 10.1016/j.urology.2004.09.036
Dergi Adı: UROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.369-373
Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives. To assess the clinical efficacy of tolterodine prescribed to children with non-neurogenic daytime urinary incontinence secondary to overactive bladder who had previously failed to improve with oral oxybutynin treatment and its relation to the side-effect profile and compliance status.